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Summary.-A soft-agar diffusion-chamber technique was used to grow colonies
from human melanoma xenografts. Plating efficiencies ranged from 0.042o% to 750,
and increased with serial passage of some tumours. Cells in colonies were similar to
human melanoma cells in morphology, histochemistry and ultrastructure, and were
shown by immunofluorescence to contain human antigens. Xenograft tumours could
be regrown from the colonies when re-implanted into immune-deprived mice.
Cell-survival curves were constructed from 5 xenograft lines treated with 4 cyto-
toxic drugs. All lines were resistant to adriamycin, but each line appeared to have an
individual spectrum of sensitivity to the more effective drugs. The responses were
compatible with the clinical pattern of response in melanoma, and in 2 cases the
objective response of lung metastases to treatment with melphalan was consistent
with the xenograft cell-survival data. Dose-response curves were exponential for
treatment with methyl-CCNU and melphalan, but distinct plateaux were seen for
2 xenografts treated with doses of DTIC over 100 mg/kg. These were thought to be
due to resistant subpopulations of clonogenic cells within the tumours.
THE VALUE of human xenografts in
therapeutic cancer research will depend
upon two main factors: on the clear
demonstration that xenografts retain the
biological and therapeutic response char-
acteristics of the source tumours, and
upon the availability of methods by which
tumour response can reliably be quanti-
fied. Most investigations have so far in-
volved the measurement of the volume
response to therapy of xenografts, especi-
ally the degree of tumour growth delay.
Such measurements are particularly
vulnerable to host rejection mechanisms
(Steel et al., 1980).
The measurement of the survival of
colony-forming cells after treatment is an
alternative endpoint of tumour response,
which has been widely applied to experi-
mental and animal tumours. (1lonogenic
cell-survival studies have been reported
for pancreatic and colonic carcinoma
xenografts treated with cyclophosphamide
(Smith et al., 1976; Courtenay & Mills,
1978) and xenografts of various histo-
logical types treated with radiation
(Courtenay et al., 1976; Guichard et al.,
1977: Smith et al., 1978). In the present
work we have sought to study further the
applicability of clonogenic cell survival
studies to human tumour xenografts, to
confirm that colonies originatefrom human
tumour cells, and to assess the clinical
impact of the results. A series of human
tumour xenografts was established in
immune-deprived mice and compared with
their source tumours (Selby et al., 1.980).
Five xenografts of a single histological
type (melanoma) were then the subject of
detailed cell-survival studies, using a
range of clinically relevant chemothera-
peutic agents. The use of the melanoma
xenograft to develop an in vitro test of
human tumour-cell chemosensitivity has
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previouislv been reported (Bateman et al.,
1 980).
MATERIALS AND METHODS
Imrimunosuppressed mice anid turmours.-
CBA/lac mice were immunosuppressed by
thymectomy, cytosine arabinoside pretreat-
ment and irradiation, according to the
method of Steel et al. (1978). Xenografting
mnethods and studies ofthe tumours have been
described previously (Selby et al., 1980).
The present studies were performed before
the 5th passage ofall tumours, except HX34,
which was studied in the 12th-17th passages
as well as in the first 4 passages from frozen
material.
Colony growth and characterization.-
Tumour pieces were taken aseptically from
1cm. diameter xenografts and washed in
phosphate-buffered saline. They were minced
with crossed scalpels, taken up into Ham's
F12 medium with 20% Special Bobby Calf
Serum (Gibco) and shaken firmly to free
single cells. Enzymatic digestion was not
used. The cell suspensions were then washed
in medium with serum and filtered through a
20,um nylon mesh. The entire procedure was
carried out under sterile conditions in a
laminar downfloN cabinet. Cell suspensions
were counted in a haemacytometer under a
phase-contrast microscope after adding liss-
amine green. Bright cells which excluded the
dye were regarded as viable. Colonies were
grown in soft agar in diffusion chambers
incubated in the peritoneal cavities of pre-
irradiated mice according to the method of
Smith et al. (1976).
For studies of colony cell morphology, the
chambers containing colonies in agar were
fixed in Bouin's solution for 24 h and the agar
transferred to 700% ethanol. The fixed agar
was paraffin-embedded and sections were cut
and stained. For enzyme histochemistry, it
proved possible to freeze the semi-solid agar
and cut frozen sections on a standard cryo-
stat. Sections were stained with haematoxylin
and eosin, and also the Fontana silver-
impregnationi technique for melanin. Histo-
chemical techniques for localization of the
enzymes dopa-oxidase and non-specific
esterase were also used. For electroni micro-
scopy, 1-2mm cubes of agar containing
colonies were fixed and examined by standard
inethods. Human antigens were identified in
colonies by a simple immunofluorescence
technique pieviously described (Selby et al.,
1980).
Cell survival measuremen1ts -Mice bearing
tumours of about 1cm diameter wvere treated
wvith i.p. injections ofthe drug under test and
the tumours excised 18 h later. Cell suspen-
sions were prepared and colony growth
assayed. No significant change in cell yield
was observed with the drugs tested. The sur-
viving fraction of clonogenic cells for each
dose level was calculated as the ratio of the
plating efficiency of treated tumours to that
of untreated, control tumours. A minimum of
two separate experiments was performed for
each drug.
Drugs.-The drugs selected for this study
were dacarbazine (DTIC, Dome Laboratories)
and methyl-CCNU (NCJ), chosen because
they are widely recognized as being among
the more efficacious available for the treat-
ment of malignant melanoma (Constanza et.
al., 1977); melphalan (Alkeran, Wellcome)
because it is now being investigated exten-
sively at this hospital in high-dose treatment
of metastatic melanoma (McElwain et al.,
1979); and adriamycin (Pharmitalia) because
this widely used drug has been ineffective
against malignant melanoma and serves as a
negative control (Sieper et al., 1975). Methyl-
CCNU wNas dissolved in dimethylsulphoxide
and diluted in 5% Tween-80 detergent (BDH
Chemicals) in saline. The other drugs were
prepared according to manufacturers' in-
structions, and all wvere used immediately
after preparation.
RESULTS
Colony growth was studied in cell sus-
pensions prepared from the 10 human
melanoma xenografts using the agar
diffusion-chamber technique. Five ofthese
tumour lines were treated with drugs and
clonogenic cell survival was measured.
Colony growth
Plating efficiency.-The PEs for the
melanoma xenografts are shown in Table I.
Colonies grew from all xenografts tested,
with PE ranging from 0-042 to 7500. All
except HX45 gave PE > 100 and HX34,
41 and 47 consistently gave PE > 10%.
In HX4], PE increased 5-fold between
Passages 1 and 4, and smaller increases in
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PE were observed through serial passage
of 4 other xenograft lines. A linear rela-
tionship between the number of cells
plated and the number of colonies growing
was obtained for all xenograft lines. The
addition of rat red blood cells (RBC)
increased the plating efficiency of 5 xeno-
grafts and decreased that of 3. The figures
quoted in Table I for PE refer to values
obtained with red blood cells when they
led to an increase, or without if they did
not.
Colony morphology and histology.
Colonies varied among xenografts in
density, regularity of outline and degree
of cell packing. They were essentially com-
pact, but for some tumours individual cells
could be distinguished at the edges, whilst
for others this was not possible. Histo-
logical sections showed the colonies to be
compatible with the tumour of origin in
cell morphology and pigmentation. Large
compact colonies were shown to have
necrotic centres. Dopa-oxidase, an enzyme
specific to the melanin biosynthetic path-
way, was demonstrated in frozen sections
of colonies from HX41. Non-specific
esterase, specific for mononuclear phago-
cytic cells, was not demonstrated in any
of the compact colonies studied. Under
electron microscopy, colonies from HX41
consisted of cells similar in ultrastructure
to those seen in the xenografted tumour
(Fig. 1). Numerous melanin granules and
melanosomes, with their characteristic
internal structure, were seen. The melanin
content of colony cells appeared to be
more uniform than in the xenograft
(Selby et al., 1980). Lipid droplets were
prominent in many ofthe cells and phago-
.:-- -: - -
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FIa. l. Electron micrograpli of cells from a colony of HX41. MIelanin granules an(l melainosomes
are seen together wsith numerous lipid (liroplets. ( x 6.000).
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TrABLE 1. Platiny fJiciency for human
melanoma xenografts in ayar diffusion
chambers
HX
No.
34
40
41
42
45
46
47
50
52
56
Yiel(d
(x 106
cells;/g)
1.0
0-5-1 0
1 0
0-1
0 1
05-1-0
1.0
1 ()
0-5-10
1.0
P)E*
10-50
2-13
10-75
13
0 042
2-6
3-5-18
4-7
3.7
3-20
Effect of rat
RBC added
to clhamber
None
Increase
Increase
Increase
NT
Sliglht increase
D)ecrease
Sliglit decrease
Increase
Decrease
Effect of
serial
passage
Variable
Increase
Increase
NT
NT
None
Increase
Increase
NT
Increase
* Colonies per l0( cells plated, tn(ler optimum
cultture conditions.
NT: not teste(d.
cytic cells were not seen in colonies.
Ultrastructural studies on colonies from
HX47 were also compatible with their
tumour of origin. Melanin granules and
melanosomes, although present, were less
numerous in the colonies than in the xeno-
graft. The cytoplasm of many cells con-
tained numerous dense bodies, mainly
amorphous, but occasionally crossed by
pale lines. The nature ofthese is uncertain,
but they may represent lipid droplets in
an unusual form.
Immune fluorescence.- Histological sec-
tions offixed agar colonies from HX34, 40,
41, 46 and 47 were tested for the presence
of human antigens, using immunofluores-
cence. The compact tumour colonies were
found to fluoresce brightly under these
conditions, illustrating their human origin.
There was a low level of nonspecific back-
ground uptake of fluorescein conjugate by
the agar.
Tumour grouth from colonies. Colonies
of HX34 and 41 were removed from the
agar with a Pasteur pipette and im-
planted, in groups of2-3, s.c. into immune-
deprived mice. These colonies grew on one
occasion for each xenograft, to form
tumours that were histologicallv com-
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FiG. 2. Cell surxviv al in melanoma xeniograft HX34 after treatment with melplhalan (left panel).
The ttumour wNas treate(d in late passages (0) and again wlhen re-establishled from material stored
in liqtid N2 (A). Tle riglht land panel shows (ell surviv\al after treatment with melplhalanin melanoma
xenografts HX41 (CO), 40 (0), 46 (A) ancd 47 (J-). LDIo was 15 mg/kg.
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FiG. 3. Cell survival after treatment with MeCCNU of the melanoma xeinografts. HX34 was treate(d
in late passage (@b) and in early passage (A) after re-establishment from liqui(d N2 (left-han(d panel).
LD)10 dose was 30 mg/kg.
40
patible with the original tumour. The
tumours which were established from
colonies of HX34 were analysed for their
karyotype and the cells contained the
same number of chromosomes as the
original xenograft tumour.
Diffuse colonies-.Although compact
colonies with the above characteristics
predominated, some very diffuse colonies
which were morphologically quite distinct
were occasionally seen. In 8 xenografts
they were uncommon and never accounted
for more than 1 of colonies seen. In
HX40 and 46they were more numerous and
accounted for up to 3000 of colonies seen
in some experiments. The proportion of
diffuse colonies varied between experi-
ments in these two xenografts, but no
general trend in their proportion could be
discerned with increasing passage. The
cells forming diffuse colonies were morpho-
logically unlike tumour cells and appeared
to be mononuclear cells with abundant
foamy cytoplasm. They contained no pig-
ment and appeared on histochemical
staining to contain non-specific esterase,
although there was substantial back-
ground staining of the agar. Sections cut
from agar containing colonies ofHX40 and
HX46 were tested by the immuno-
fluorescence technique. Whilst compact
colonies fluoresced brightly, cells in diffuse
colonies did not, suggesting their non-
human origin. We conclude that the agar
diffusion chambers may be able to support
the clonal growth of macrophage pre-
cursors, as found in in vitro cultures of
murine tumours by Stephens et al. (1978).
Cell-survival studies
The cell survival data are presented in
Figs 2 to 5. For 3 ofthe drugs (melphalan,
MeCCNU and adriamycin) the highest
dose used was -LD10 (see legends and
footnote to Table II). In the case of
DTIC, doses up to 2 x LD10 were used in
order to investigate the nonlinear form of
the curves. For melphalan and MeCCNU,
almost all the curves are consistent with
exponential cell kill. After linear regres-
sion analysis, only in the case of HX47
treated with melphalan was the origin ouit-
. 1.
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Fic:. 4. Cell survival after treatment with 1)TIC of melainoma xeniograft HX34 in late passage ( 0)
an(l after re-establisbimenit (A) (left panel), also HX41 an(d HX47. LD1o was 200 mg/kg.
r'ABLE II. Dose-response curves of mel-
anoma xenografts to melphalan and
MeCCNU
Dr-ug HX
MeIplpalan :14
40
41
46
47
M\IeCC'NU :14
40
41
46
47
-)Jo*
6-5 (6-0-7-1)
7-0 (5 6-9 2)
20 8 (12-2-70.1)
4-8 (4-1-5-8)
6-2 (5.7-6.7)t
4-4 (3 8-5 2)
10-2 (7-:3-17)
poorly (lefine(d
15-7 (11 0-27 4)
8 9 (6-:3-14 8)
Survivxilng
fraction at
LDIoT
0(008
0-008
(015
(().0008)
(0009
(10-7)
((00015)
()-1
0-02
0-0002
* Dose in mg/kg for 10% cell survival alonig regres-
sion line; 95% confidence limits in brackets.
t Significant shoulder, estimated at 2-4 mg/kg
(confidence limits 1-2-3-4).
+ Values in brackets were obtainedl by extrapola-
tion. LD10 values for immunosuppressed CBA mice
wvere melplbalan 15 mg/kg, M\IeCCNU 30 mg/kg.
side the 95% confidence limits ofthe inter-
cept ofthe regression line with the vertical
axis. In most cases therefore a single
parameter suffices to represent the sensi-
tivity of the tumours to these drugs, and
we have chosen the dose required to
reduce cell survival by one decade (Dio);
values for D1o are given in Table II. A
variance-ratio (F) test was used to com-
pare the variance ofthese parameters, and
the significance ofdifferences in sensitivity
was assessed using a t or d test as appro-
priate.
For melphalan, there were no significant
differences in DIo values among HX34, 40
and 47. HX41 had a significantly greater
value (i.e. was less sensitive) whilst HX46
had a significantly lower value (P < 0.05).
In the case of HX34, cell survival was
examined first in Passages 12-15, then
later in the first passage ("PNJ ") of the
original tumour material that had been
stored in liquid N2. There was no signifi-
cant change in sensitivity due to storage
or serial passage.
With MeCCNU, the DIO values were
statistically indistinguishable for HX40,
46 and 47, but HX34 was significantly
more sensitive. The scatter in the data for
HX41 did not allow its sensitivity to be
reliably evaluated, though it appeared to
be more resistant than the other tumotur
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lines. Studies on frozen mnaterial of HX34
again confirmed the more detailed studies
on the 12th-15th passages of unfrozen
tumour.
The response of 3 of the tumour lines to
DTIC was evaluated. HX41 was insensi-
tive, having a Djo > 500 mg/kg. HX34 and
47 were much more sensitive, but both
showed evidence for saturation in the cell-
killing effect at high doses. The maximum
tolerated single dose of DTIC is 200 mg/
kg, and doses well in excess of this value
were used in this instance to confirm the
existence of the plateaux. With both these
tumour lines the initial component of cell
killing was very steep, the first decade of
cell kill requiring a dose of only 20 mg/
kg. In each case the plateau was reached
at a survival of - 5 x 10-3. Cells of the 4th
passage out of liquid N2 storage again had
a similar sensitivity to the unfrozen
tumours.
Fig. 5 shows cell-survival data for all 5
xenografts treated with adriamycin. In no
case was survival below 0 5.
The effect of modifying the time of
assay after drug administration was stud-
ied in HX34 for all 4 drugs. In no case
was there a significant change in cell
survival when assay was delayed from 3
to 18 h.
1
z
0
U)
.01
z
.01
i IIX34
* HIX40
O HX41
O HX46
A\ fIX47
Comparisons betueen xenoyraft and donor
patient response
This study was not designed to seek
correlation between cell-survival curves
ofindividual melanomas as xenografts and
the response of the same tumour to treat-
ment in the patient. However, 2 patients
whose tumours were studied as xenografts
were treated with melphalan and com-
parison of their responses is possible.
Fig. 6 shows the volume oflung metastases
estimated from chest radiographs in these
2 patients after i.v. treatment with
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Ficn. 6. Clinical response oflutngmetastases in
2 (loinor patients (upper panel). Voltume of
2 measurable lung metastases in the (lonor of
HX47 (0) ain(l oine metastasis in the (lonor
of HX41 (jA ) were measuredl after treat-
ment witlh melphalan 140 mg/M2 i.v. at
thle time indlicatedl by the arrow. The lower
paniel slhows the melplalan cell-sturx'ival
curves for the correspon(ling xenografts,
establislhe(d before thle melphalan treatment.
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melphalan at 140 mg/M2. The patient
from whom xenograft HX47 originated
had a substantial response to this treat-
ment, with marked reduction in the
volume of one lung metastasis and dis-
appearance of another. Unfortunately,
this response in the patient was transient;
the metastases regrew quickly and the
patient died with overwhelming disease.
The xenografts from this patient ranked
second in response to melphalan (Table II)
with a survival at the LD,o of <1%.
The patient from whom HX41 origin-
ated was treated with a similar dose of
melphalan, with very little effect on the
measurable lung metastases or his
cutaneous and hepatic metastases. This
patient died with extensive disease 3
weeks after treatment. The tumour as a
xenograft was also less sensitive than
HX47 and the surviving fraction of
clonogenic cells was > 10% at the LD10.
In separate experiments, the results of
which are not shown, the serum levels of
melphalan, measured by mass spectro-
scopy by Dr M. Jarman of this Institute
or using radio-labelled melphalan, have
been shown to be similar in mice receiving
an LD10 dose and in patients receiving
140 mg/M2 i.v.
DISCUSSION
Colony growth
The direct evidence that colonies scored
in the present study were derived from
human tumour cells was strong. They were
compatible with the tumour-of-origin in
cell morphology, karyotype, ultrastruc-
ture, pigment content and enzyme con-
tent, and they contained human antigens
demonstrated by immune fluorescence. In
the case of HX34 and 41, the re-implanta-
tion of colonies into immunosuppressed
mice produced tumours resembling un-
cloned xenografts. It seems likely that the
"diffuse" colonies were derived from
mouse cells of the macrophage series, as
found by Stephens et al. (1978). They were
morphologically suggestive of mono-
nuclear phagocytes, were probably posi-
tive for non-specific esterase and did not
bear human antigens demonstrable by
immunofluorescence. Although in the pres-
ent work it seemed simple to distinguish
tumour-cell from non-tumour-cell colonies
when scoring the chambers, there clearly
is a potential pitfall here in cell survival
and cloning studies on xenografts.
The quoted plating efficiencies (Table I)
were determined as the ratio of colonies
scored to the number of viable cells
plated, the latter being counted on a
haemacytometer, using size and morph-
ology to distinguish tumour and stromal
cells. This distinction is unlikely to be
absolute, and it is thus possible that some
non-malignant cells were counted and
included in the denominator of the ratio.
This possibility must be borne in mind in
interpreting the plating efficiencies quoted,
and may represent a source of error in
some circumstances. This might have been
reduced by using a characteristic such
as enzyme histochemistry or immuno-
fluorescence to identify tumour or non-
tumour cells; a few preliminary experi-
ments indicated that this approach to
analysis of xenograft cell suspensions is
feasible.
A substantial increase in plating effici-
ency after serial passage was observed in
HX41. This increase might reflect an in-
crease in the proportion of clonogenic cells
within the xenograft tumours as a result
of cell selection, though this was not
reflected in tumour morphology. It is
possible that an increase in the propor-
tion of clonogenic cells could lead to
altered patterns of response to certain
drugs.
Clonogentc cell survival
This is the first study in which it has
been possible to measure cell survival after
therapy ofa range ofhuman tumour xeno-
grafts of a single histological type. Cell
survival provides an important alternative
to tumour growth delay or tumour cure
for assessing the response to treatment of
tumours including xenografts, and pro-
vides a measure of cell kill that is uncorn-
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plicated by the effects of host response
upon the tuimours. In addition to the pres-
ent study of humaan melanoma xeno-
grafts, the success of cloning colonic, oat-
cell, uterine and ovarian carcinomas in
diffusion chambers (Smith et al., 1976,
1978, and unpublished observations) sug-
gests that this approach may be extended
to a wide range of tumour types.
In clinical chemotherapy it is widely
accepted that there is considerable hetero-
geneity in the chemoresponse of histo-
logically similar tumours. However, the
underlying mechanisms of this hetero-
geneity are not readily studied in the
clinic, because of the wide range of drug
doses and individual variations in phar-
macokinetics that are encotuntered there.
One of the objects of this project was to
examine whether each of a group of
similar xenograft lines had the samne
spectrum of response to a range of dlrugs,
or whether they showed evidence of indi-
viduality in response. The answer to this
question is important in decisions whether
a small group ofxenografts ofone type can
be used as chemotherapeutic test systems
for these tumours in general, or whether
attempts must be made to choose the best
drug for the individual patient. Our coIn-
clusions may be set out as follows:
(i) There were some large differences in
sensitivity among the 5 tumour lines
to individual drugs, particularly
methyl CCNU and DTIC.
(ii) There was evidence that the 5 tumour
lines showed some similarities in their
ranking ofthe 4 drugs. Only in HX34
and 47 were all 4 drugs accurately
assessed, and in both these tumour
lines the ranking of the drugs in de-
creasing order of cell kill at the LDIO
dose was MeCCNU > DTIC > melph-
alan > adriamycin. The data were
analysed by Friedman's 2-way
analysis of variance by ranks (Siegel,
1956) and this confirmed that the
ranking of dIrugs was not random
(P >0.05).
(iii) Among the 3 most effective agents
there wNas evidence for individualitv
in the drug responise of the 5 tumour
lines. HX41 was probably resistant to
all 3 agents. HX34 was very sensitive
to MeCCNU, irrespective of the num-
ber of passages. HX46 was signifi-
cantlv more sensitive to melphalan
than were the other tumour lines.
This supports the conclusion that a
laboratory test which allowed these
drugs to be reliably ranked for each
patient might have a useful impact on
the clinical chemotherapy of melan-
oma, and perhaps other huiman
tuumours.
The observation of exponential cell-
survival curves for melphalan and
MeCCNU is in keeping with published
work oni animal tumours (Valeriote &
Tolen, 1972; Hill & Stanley, 1975) and in
in vitro cell lines (Barlogie & Drewinko,
1977; Barranco et al., 1978). This result
supports the hypothesis that greater
therapeutic effect against a tumour may
be anticipated when higher doses of these
agents are used in man, providing that
increased toxicity to the patient cani be
circumvented or effectively treated
(McElwain et al., 1979).
The finding of plateaux in the dose-
response curves of HX34 and HC47 to
DTIC was surprising, however. We are
unaware of evidence that the pharma-
cology of DTIC leads to a limitation or
saturation ofthe drug effect at high doses,
or that it has cycle-specificity (Sym-
posium on DTIC, 1976). Cycle specificity
is unlikely to be the explanation for the
plateaus, because they occurred below
10-2 cell survival, and a time-survival
study showed that this level was reached
within 3 h. It therefore seems likely that
the plateaus were due to resistant popula-
tions of clonogenic cells within the
tumours. In colonies from HX47 surviving
DTIC (150 mg/kg) human antigens were
demonstrated in the cells by imnmuno-
fluiorescence, making it unlikely that they
were colonies ofmurine inflammatory cells.
Coomparison wvith clinical response
The relative effectiveness of the 4 (Iruigs
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against these melanoma xenografts was
consistent with clinical experience. Adria-
mycin was singularly ineffective against
all the melanomas, and is known to be
ineffective against clinical metastatic
melanoma (Sieper et al., 1975). MeCCNU
and DTIC were effective against some
tumours, but not all, which is observed in
clinical practice (Constanza et al., 1977).
Melphalan was moderately effective
against 4 of the melanomas when given in
maximum tolerated doses, in keeping
with the results from high doses of
melphalan to treat patients with meta-
static melanoma. A substantial proportion
of such patients achieve partial remissions
and a few tumours regress completely
(McElwain et al., 1979).
The two direct comparisons between the
cell-survival curves ofthe melanoma xeno-
grafts and the clinical response of the
donor patients are encouraging. This adds
to the growing body of evidence that the
chemosensitivity of individual human
tumours is retained in their xenografts
(Nowak et al., 1978; Giovanella et al.,
1978; Shorthouse et al., 1980) and sug-
gests that the use of this precise, quanti-
fiable endpoint will prove valuable in
further studies ofthis question.
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